NOV 22, 2022 6:00 PM PST

Non-Opioid Drug Moving to Phase 3 of Clinical Trials

WRITTEN BY: Amielle Moreno

For a long time, researchers have strived to discover new treatments for pathological pain. One focus has been to find a method of blocking sodium channels on nociceptor neurons. Now Vertex pharmaceuticals is announcing its non-opioid pain reliever, VX-548, will advance to Phase 3 clinical trials during the 2022 fourth quarter. The hope is this drug will offer a new and non-addictive alternative to opioid-based pain treatments.

Pain is supposed to warn us of a threat, but when it becomes chronic, it can have debilitating effects. Pathological pain is generally chronic and entails normally harmless sensations eliciting pain. It includes pain involving nerve injury (neuropathic) and tissue injury related inflammation. While opioids address acute pain well, they fall short when used as a pathological pain treatment.

NaV1.8 is a sodium voltage-gated channel that plays a role in peripheral nervous system pain signaling. It is selectively expressed on neurons whose cell bodies reside within the dorsal root ganglion near the spinal cord. This ion channel is highly expressed on neurons carrying pain information called nociceptors. The channel is linked to neuropathic but more prominently inflammatory pain. There’s evidence suggesting NaV1.8 has an effect on neighboring uninjured neurons, leading to their hyperexcitability.

Vertex’s VX-548 contains small, NaV1.8 channel targeting molecules to decrease or block activity. The oral medication’s Phase 3 clinical trial will include participants recovering from bunionectomy or abdominoplasty surgery. They will be randomly assigned in the double-blind and placebo-controlled study. Pain will be measured after 48 hours of treatment using the Numeric Pain Rating Scale. Proof-of-concept research indicated this treatment could aid in acute, neuropathic, and musculoskeletal pain.

It's been decades since the last non-opioid pain treatment was approved for consumer use. Vertex is hoping to “bring forward a medicine that delivers effective pain control without addictive potential to patients who are waiting” said Carmen Bozic, M.D., Executive Vice President of Vertex in their press release.

Sources: Vertex, Molecular Pain
 

About the Author
Doctorate (PhD)
Amielle Moreno earned her doctorate in neuroscience from Emory University and has dedicated her career to science communication, news coverage, and academic writing/editing. She is a published researcher who has branched out to author articles for various science websites. She is currently preparing a second academic manuscript for submission. It will detail her findings on how sensory areas of the brain respond to social sound. When she's not writing or editing, you can find her spinning the latest neuroscience news into comedy gold, hosting her podcast "Miss Behavior Journal Club." This fortnightly humorous podcast features the latest in behavioral research. Her goal in life is to defend and discover scientific truths.
You May Also Like
NOV 28, 2022
Neuroscience
Modified 'Bath Salts' Hold Potential to Treat Depression
Modified 'Bath Salts' Hold Potential to Treat Depression
Experimental synthetic drugs may treat depression and anxiety-related disorders with few adverse side effects. The corre ...
NOV 29, 2022
Drug Discovery & Development
75g Kale Per Day Could Keep Bone Fractures Away
75g Kale Per Day Could Keep Bone Fractures Away
Vitamin K1- a nutrient found in leafy greens like kale, cabbage, and spinach- may help reduce bone fracture risk in elde ...
NOV 29, 2022
Drug Discovery & Development
Chemotherapy May Increase Disease Susceptibility for Two Generations
Chemotherapy May Increase Disease Susceptibility for Two Generations
A common chemotherapy drug may make future generations more susceptible to disease. The corresponding study was publishe ...
DEC 21, 2022
Neuroscience
The Antidepressant in Everyone's Medicine Cabinet: The case for the inflammatory theory of depression grows
The Antidepressant in Everyone's Medicine Cabinet: The case for the inflammatory theory of depression grows
Compared to the countless number of serotonin and dopamine-centered depression studies, the kynurenine pathway (KP) hold ...
DEC 30, 2022
Health & Medicine
Individuals in Mid-Adulthood Sleep Less Than Younger and Older Adults
Individuals in Mid-Adulthood Sleep Less Than Younger and Older Adults
A study published in Nature Communications found that people sleep less on average in mid-adulthood than in early and la ...
JAN 11, 2023
Plants & Animals
Canadian sea sponge contains COVID-blocking compounds
Canadian sea sponge contains COVID-blocking compounds
Since the start of the COVID-19 pandemic, researchers have studied the virus with a near singular purpose: finding ways ...
Loading Comments...